Annual FCF
-$162.37 M
-$72.19 M-80.05%
31 December 2023
Summary:
Lexicon Pharmaceuticals annual free cash flow is currently -$162.37 million, with the most recent change of -$72.19 million (-80.05%) on 31 December 2023. During the last 3 years, it has fallen by -$19.31 million (-13.50%). LXRX annual FCF is now -188.31% below its all-time high of $183.87 million, reached on 31 December 2015.LXRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$53.93 M
-$5.14 M-10.53%
30 September 2024
Summary:
Lexicon Pharmaceuticals quarterly free cash flow is currently -$53.93 million, with the most recent change of -$5.14 million (-10.53%) on 30 September 2024. Over the past year, it has dropped by -$12.22 million (-29.31%). LXRX quarterly FCF is now -120.30% below its all-time high of $265.68 million, reached on 31 December 2015.LXRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$208.39 M
-$12.22 M-6.23%
30 September 2024
Summary:
Lexicon Pharmaceuticals TTM free cash flow is currently -$208.39 million, with the most recent change of -$12.22 million (-6.23%) on 30 September 2024. Over the past year, it has dropped by -$73.76 million (-54.79%). LXRX TTM FCF is now -213.34% below its all-time high of $183.87 million, reached on 31 December 2015.LXRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LXRX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -80.0% | -29.3% | -54.8% |
| 3 y3 years | -13.5% | -210.6% | -109.1% |
| 5 y5 years | -9.2% | -128.3% | -287.8% |
LXRX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -84.0% | at low | -210.6% | +2.2% | -140.8% | at low |
| 5 y | 5 years | -242.8% | at low | -128.3% | +2.2% | -277.6% | at low |
| alltime | all time | -188.3% | +12.5% | -120.3% | +37.0% | -213.3% | +4.3% |
Lexicon Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$53.93 M(+10.5%) | -$208.39 M(+6.2%) |
| June 2024 | - | -$48.79 M(-11.5%) | -$196.17 M(+5.7%) |
| Mar 2024 | - | -$55.13 M(+9.1%) | -$185.64 M(+14.3%) |
| Dec 2023 | -$162.37 M(+80.1%) | -$50.55 M(+21.2%) | -$162.37 M(+20.6%) |
| Sept 2023 | - | -$41.70 M(+9.0%) | -$134.63 M(+19.8%) |
| June 2023 | - | -$38.26 M(+20.1%) | -$112.38 M(+14.0%) |
| Mar 2023 | - | -$31.86 M(+39.6%) | -$98.54 M(+9.3%) |
| Dec 2022 | -$90.18 M(+2.2%) | -$22.82 M(+17.3%) | -$90.18 M(-0.0%) |
| Sept 2022 | - | -$19.44 M(-20.4%) | -$90.21 M(+2.4%) |
| June 2022 | - | -$24.42 M(+3.9%) | -$88.13 M(+1.8%) |
| Mar 2022 | - | -$23.50 M(+2.8%) | -$86.54 M(-1.9%) |
| Dec 2021 | -$88.24 M(-38.3%) | -$22.85 M(+31.6%) | -$88.24 M(-11.5%) |
| Sept 2021 | - | -$17.36 M(-23.9%) | -$99.68 M(-18.8%) |
| June 2021 | - | -$22.83 M(-9.4%) | -$122.73 M(-16.1%) |
| Mar 2021 | - | -$25.20 M(-26.5%) | -$146.20 M(+2.2%) |
| Dec 2020 | -$143.06 M(-225.8%) | -$34.29 M(-15.1%) | -$143.06 M(+7.5%) |
| Sept 2020 | - | -$40.41 M(-12.7%) | -$133.13 M(-235.9%) |
| June 2020 | - | -$46.30 M(+109.9%) | $97.97 M(-16.5%) |
| Mar 2020 | - | -$22.05 M(-9.5%) | $117.37 M(+3.2%) |
| Dec 2019 | $113.74 M(-176.5%) | -$24.37 M(-112.8%) | $113.74 M(+2.5%) |
| Sept 2019 | - | $190.70 M(-808.9%) | $110.94 M(-208.8%) |
| June 2019 | - | -$26.90 M(+4.7%) | -$101.94 M(-20.1%) |
| Mar 2019 | - | -$25.69 M(-5.4%) | -$127.58 M(-14.2%) |
| Dec 2018 | -$148.70 M(-19.9%) | -$27.16 M(+22.5%) | -$148.70 M(-4.2%) |
| Sept 2018 | - | -$22.18 M(-57.8%) | -$155.25 M(-7.1%) |
| June 2018 | - | -$52.54 M(+12.2%) | -$167.09 M(+13.8%) |
| Mar 2018 | - | -$46.81 M(+38.9%) | -$146.85 M(-20.9%) |
| Dec 2017 | -$185.62 M(+5.6%) | -$33.72 M(-0.9%) | -$185.62 M(-7.6%) |
| Sept 2017 | - | -$34.02 M(+5.3%) | -$200.85 M(-0.6%) |
| June 2017 | - | -$32.30 M(-62.3%) | -$202.06 M(-7.2%) |
| Mar 2017 | - | -$85.59 M(+74.9%) | -$217.65 M(+23.8%) |
| Dec 2016 | -$175.86 M(-195.6%) | -$48.94 M(+38.9%) | -$175.86 M(-226.7%) |
| Sept 2016 | - | -$35.23 M(-26.4%) | $138.76 M(-6.4%) |
| June 2016 | - | -$47.89 M(+9.4%) | $148.32 M(-9.3%) |
| Mar 2016 | - | -$43.79 M(-116.5%) | $163.57 M(-11.0%) |
| Dec 2015 | $183.87 M(-342.9%) | $265.68 M(-1135.0%) | $183.87 M(-313.0%) |
| Sept 2015 | - | -$25.67 M(-21.4%) | -$86.30 M(+5.5%) |
| June 2015 | - | -$32.64 M(+38.9%) | -$81.83 M(+18.8%) |
| Mar 2015 | - | -$23.50 M(+423.2%) | -$68.86 M(-9.0%) |
| Dec 2014 | -$75.70 M(-18.4%) | -$4.49 M(-78.8%) | -$75.70 M(-18.7%) |
| Sept 2014 | - | -$21.20 M(+7.8%) | -$93.17 M(-3.1%) |
| June 2014 | - | -$19.67 M(-35.2%) | -$96.17 M(-1.9%) |
| Mar 2014 | - | -$30.35 M(+38.2%) | -$98.04 M(+5.6%) |
| Dec 2013 | -$92.80 M(-2.3%) | -$21.96 M(-9.3%) | -$92.80 M(+1.5%) |
| Sept 2013 | - | -$24.20 M(+12.4%) | -$91.39 M(-1.0%) |
| June 2013 | - | -$21.53 M(-14.3%) | -$92.31 M(-0.6%) |
| Mar 2013 | - | -$25.11 M(+22.2%) | -$92.83 M(-2.2%) |
| Dec 2012 | -$94.95 M | -$20.55 M(-18.2%) | -$94.95 M(-2.2%) |
| Sept 2012 | - | -$25.12 M(+13.9%) | -$97.11 M(+5.1%) |
| June 2012 | - | -$22.05 M(-19.0%) | -$92.39 M(-2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$27.24 M(+20.0%) | -$94.33 M(+5.8%) |
| Dec 2011 | -$89.14 M(+6.8%) | -$22.70 M(+11.3%) | -$89.14 M(+3.5%) |
| Sept 2011 | - | -$20.40 M(-15.0%) | -$86.11 M(+1.7%) |
| June 2011 | - | -$24.00 M(+8.8%) | -$84.66 M(+1.6%) |
| Mar 2011 | - | -$22.05 M(+12.1%) | -$83.36 M(-0.2%) |
| Dec 2010 | -$83.50 M(-6.6%) | -$19.67 M(+3.8%) | -$83.50 M(+2.9%) |
| Sept 2010 | - | -$18.95 M(-16.5%) | -$81.15 M(-1.0%) |
| June 2010 | - | -$22.70 M(+2.3%) | -$81.94 M(-1.6%) |
| Mar 2010 | - | -$22.18 M(+28.1%) | -$83.26 M(-6.9%) |
| Dec 2009 | -$89.39 M(-8.6%) | -$17.32 M(-12.3%) | -$89.39 M(-3.1%) |
| Sept 2009 | - | -$19.74 M(-17.8%) | -$92.27 M(-3.4%) |
| June 2009 | - | -$24.02 M(-15.2%) | -$95.51 M(-3.2%) |
| Mar 2009 | - | -$28.31 M(+40.1%) | -$98.66 M(+0.9%) |
| Dec 2008 | -$97.79 M(+28.3%) | -$20.20 M(-12.1%) | -$97.79 M(+5.7%) |
| Sept 2008 | - | -$22.98 M(-15.4%) | -$92.50 M(+4.5%) |
| June 2008 | - | -$27.17 M(-1.0%) | -$88.54 M(+7.3%) |
| Mar 2008 | - | -$27.43 M(+83.9%) | -$82.52 M(+8.3%) |
| Dec 2007 | -$76.22 M(+26.0%) | -$14.92 M(-21.6%) | -$76.22 M(+6.4%) |
| Sept 2007 | - | -$19.02 M(-10.1%) | -$71.65 M(+4.5%) |
| June 2007 | - | -$21.15 M(+0.1%) | -$68.54 M(-0.6%) |
| Mar 2007 | - | -$21.14 M(+104.2%) | -$68.98 M(+14.0%) |
| Dec 2006 | -$60.49 M(-597.4%) | -$10.35 M(-35.0%) | -$60.49 M(+49.2%) |
| Sept 2006 | - | -$15.91 M(-26.3%) | -$40.54 M(+469.0%) |
| June 2006 | - | -$21.59 M(+70.8%) | -$7.13 M(-143.6%) |
| Mar 2006 | - | -$12.64 M(-231.7%) | $16.33 M(+34.3%) |
| Dec 2005 | $12.16 M(-122.5%) | $9.60 M(-45.2%) | $12.16 M(-260.1%) |
| Sept 2005 | - | $17.51 M(+839.7%) | -$7.60 M(-76.0%) |
| June 2005 | - | $1.86 M(-111.1%) | -$31.65 M(-41.5%) |
| Mar 2005 | - | -$16.81 M(+65.5%) | -$54.10 M(+0.1%) |
| Dec 2004 | -$54.07 M(+331.2%) | -$10.16 M(+55.1%) | -$54.07 M(+226.2%) |
| Sept 2004 | - | -$6.55 M(-68.2%) | -$16.58 M(-25.9%) |
| June 2004 | - | -$20.58 M(+22.7%) | -$22.36 M(+62.1%) |
| Mar 2004 | - | -$16.78 M(-161.4%) | -$13.79 M(+10.0%) |
| Dec 2003 | -$12.54 M(-74.2%) | $27.33 M(-321.6%) | -$12.54 M(-69.1%) |
| Sept 2003 | - | -$12.34 M(+2.7%) | -$40.59 M(-7.5%) |
| June 2003 | - | -$12.01 M(-22.6%) | -$43.86 M(-4.9%) |
| Mar 2003 | - | -$15.53 M(+2068.4%) | -$46.12 M(-5.0%) |
| Dec 2002 | -$48.56 M(+54.3%) | -$716.00 K(-95.4%) | -$48.56 M(-13.4%) |
| Sept 2002 | - | -$15.61 M(+9.4%) | -$56.08 M(+21.1%) |
| June 2002 | - | -$14.27 M(-20.6%) | -$46.29 M(+18.8%) |
| Mar 2002 | - | -$17.96 M(+118.1%) | -$38.96 M(+23.8%) |
| Dec 2001 | -$31.46 M(+241.6%) | -$8.24 M(+41.5%) | -$31.46 M(+16.8%) |
| Sept 2001 | - | -$5.82 M(-16.1%) | -$26.94 M(+4.4%) |
| June 2001 | - | -$6.93 M(-33.8%) | -$25.81 M(+26.8%) |
| Mar 2001 | - | -$10.47 M(+182.2%) | -$20.35 M(+120.9%) |
| Dec 2000 | -$9.21 M(-32.8%) | -$3.71 M(-21.0%) | -$9.21 M(+67.5%) |
| Sept 2000 | - | -$4.69 M(+219.0%) | -$5.50 M(+582.9%) |
| June 2000 | - | -$1.47 M(-320.9%) | -$805.40 K(-220.9%) |
| Mar 2000 | - | $666.20 K | $666.20 K |
| Dec 1999 | -$13.70 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual FCF year-on-year change?
- What is Lexicon Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly FCF year-on-year change?
- What is Lexicon Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM FCF year-on-year change?
What is Lexicon Pharmaceuticals annual free cash flow?
The current annual FCF of LXRX is -$162.37 M
What is the all time high annual FCF for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual free cash flow is $183.87 M
What is Lexicon Pharmaceuticals annual FCF year-on-year change?
Over the past year, LXRX annual free cash flow has changed by -$72.19 M (-80.05%)
What is Lexicon Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of LXRX is -$53.93 M
What is the all time high quarterly FCF for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly free cash flow is $265.68 M
What is Lexicon Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, LXRX quarterly free cash flow has changed by -$12.22 M (-29.31%)
What is Lexicon Pharmaceuticals TTM free cash flow?
The current TTM FCF of LXRX is -$208.39 M
What is the all time high TTM FCF for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM free cash flow is $183.87 M
What is Lexicon Pharmaceuticals TTM FCF year-on-year change?
Over the past year, LXRX TTM free cash flow has changed by -$73.76 M (-54.79%)